Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on April 23, 2025
OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th
GlobeNewswire
·
April 23, 2025
BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A …
Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025
GlobeNewswire
·
April 23, 2025
WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research …
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
GlobeNewswire
·
April 23, 2025
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other …
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 23, 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards …
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
GlobeNewswire
·
April 23, 2025
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the United States Patent and …
RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire
·
April 23, 2025
ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the …
Sight Sciences Announces the Release of its Sustainability Report
GlobeNewswire
·
April 23, 2025
MENLO PARK, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today …
OrthoPediatrics Corp. to Report First Quarter Financial Results on May 7, 2025
GlobeNewswire
·
April 23, 2025
WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to …
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
GlobeNewswire
·
April 23, 2025
NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025
GlobeNewswire
·
April 23, 2025
Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13% Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, …
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts
GlobeNewswire
·
April 23, 2025
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in …
Galapagos rapporteert resultaten over het eerste kwartaal van 2025, recente hoogtepunten en verwachtingen op korte termijn
GlobeNewswire
·
April 23, 2025
Eerste Amerikaanse patiënt gedoseerd in ATALANTA-1 studie met GLPG5101 Mantelcellymfoom (MCL), een hematologische maligniteit met een hoge onvervulde behoefte, geselecteerd als hoofdindicatie voor het GLPG5101-programma; pivotale ontwikkeling gepland voor …
United Fire Group, Inc. announces its first quarter 2025 earnings call
GlobeNewswire
·
April 23, 2025
CEDAR RAPIDS, Iowa, April 23, 2025 (GLOBE NEWSWIRE) -- United Fire Group, Inc. (Nasdaq: UFCS) (UFG) announced today that its first quarter 2025 earnings results will be released after the market closes on Tuesday, May 6, 2025. An earnings call will be held …
Telepharmacy Market Size Expected to Hit USD 10.0 Billion by 2035 with a Remarkable 5.89% CAGR
EIN Presswire
·
April 23, 2025
Telepharmacy Market Booms as Remote Pharmaceutical Care Gains Momentum US, NY, UNITED STATES, April 23, 2025 /EINPresswire.com/ -- The global Telepharmacy market is experiencing remarkable growth, driven by the increasing need for accessible healthcare, …
Healthcare IT Outsourcing Market Expected to Achieve a Strong 5.89% CAGR, to Reach USD 90.0 Billion by 2035
EIN Presswire
·
April 23, 2025
Healthcare IT Outsourcing Market Experiences Robust Growth Amidst Digital Transformation US, NY, UNITED STATES, April 23, 2025 /EINPresswire.com/ -- The global Healthcare IT Outsourcing market is witnessing significant expansion, fueled by the …
Mounfit Under Review: Natural Mounjaro Ingredients Recipe to Lose Weight Safely
GlobeNewswire
·
April 23, 2025
Aurora, Colorado, April 23, 2025 (GLOBE NEWSWIRE) -- Introduction Understanding the Modern Weight Loss Struggle In 2025, millions continue to struggle with stubborn weight gain, not because they lack willpower, but because the rules of metabolism have …
Best SARMS for Cutting and Bulking to Buy 2025 - Best SARMS for Sale for Muscle Growth, Fat Loss and Bodybuilding- By CrazyBulk
GlobeNewswire
·
April 23, 2025
Albany, New York, April 23, 2025 (GLOBE NEWSWIRE) -- If you’re looking to transform your physique with lean muscle growth, SARMs (Selective Androgen Receptor Modulators) are incredibly popular. Bodybuilders are buying SARMs for bulking and cutting and …
Sarms Vs Steroids – The Best Sarms And Legal Steroids For Cutting, Bulking And Bodybuilding In 2025 Tested And Rated – By Crazy Bulk.
GlobeNewswire
·
April 23, 2025
New York City, April 23, 2025 (GLOBE NEWSWIRE) -- SARMs are a rather new proposition on the market compared to steroids. An enthusiast of the fitness culture would admit to having heard about SARMs or steroids at some point. They enjoy a better …
Colon Broom Reviews: Weight loss,Ingredients - Does Colon Broom Work (UK,Canada/USA)- Consumer Reports & Side Effect
GlobeNewswire
·
April 23, 2025
San Francisco, California, April 23, 2025 (GLOBE NEWSWIRE) -- In a world where every other product tries to be a fiber supplement or detox product, ColonBroom is a great, high-strength formula that does its best to maximize digestive health, heal …
Industry Sciences One launches IS1 Consulting: Strategic advisory services for the life sciences sector
GlobeNewswire
·
April 23, 2025
CRANBURY, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Industry Sciences One (IS1), a division of MJH Life Sciences®, today announced the launch of IS1 Consulting, a custom consulting network designed to support decision-makers across the life sciences with …